Susan E. Senogles, Ph.D.

Susan E. Senogles, Ph.D.

Department of Microbiology, Immunology and Biochemistry

The University of Tennessee Health Science Center
858 Madison Avenue
Memphis, TN 38163
Phone: (901) 448-7077
Fax: (901) 448-7360
Email: Susan E. Senogles


  • Ph.D. Institution: University of Minnesota, Department of Biochemistry
  • Postdoctoral: Duke University, Department of Cell Biology (previously Physiology)

Research Interests

Receptors of the seven transmembrane spanning domain family, such as the receptors for dopamine and epinephrine, signal to multiple effector systems through a large family of highly homologous G proteins. The main focus of my laboratory is the biochemistry of signal transduction, with particular emphasis on the biochemical mechanisms which govern signalling fidelity. The D2 dopamine receptor appears to function by activation of a complex set of intracellular signals, including the inhibition of adenylyl cyclase, activation of potassium channels and inhibition of voltage-gated calcium channels. One useful system for the study of D2 dopamine receptor signalling is the anterior lobe of the pituitary. Dopamine secreted into the hypophyseal portal circulation by hypothalamic neurons mediates the release of prolactin from the anterior lobe of the pituitary. We use several clonal cell lines which are derived from pituitary tumors but lack the D2 dopamine receptor. These cell lines allow us to apply protein mutagenesis and transfection techniques to define regions of the receptor which dictate the specificity of G protein interactions. We also are using several protein mutagenesis strategies to define the specificity of G protein coupling to a given effector, as well as defining domains on the G proteins which are specific for both receptor and effector interaction.

Representative Publications

  • Pi M, Kapoor K, Wu Y, Ye R, Senogles SE, Nishimoto SK, Hwang DJ, Miller DD, Narayanan R, Smith JC, Baudry J, Quarles LD. Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues. Mol Endocrinol. 2015 Dec;29(12):1759-73. doi: 10.1210/me.2015-1161. Epub 2015 Oct 6. PubMed PMID: 26440882; PubMed Central PMCID: PMC4664231.
  • Kendall RT, Senogles SE. Isoform-specific uncoupling of the D2 dopamine receptors subtypes. Neuropharmacology. 2011 Feb-Mar;60(2-3):336-42. doi: 10.1016/j.neuropharm.2010.09.018. Epub 2010 Oct 1. PubMed PMID: 20888845.
  • Everett PB, Senogles SE. D3 dopamine receptor signals to activation of phospholipase D through a complex with Rho. J Neurochem. 2010 Feb;112(4):963-71. doi: 10.1111/j.1471-4159.2009.06508.x. Epub 2009 Dec 18. PubMed PMID: 20021566.
  • Senogles SE. D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs. 2007 Aug;18(7):801-7. PubMed PMID: 17581302.
  • Kendall RT, Senogles SE. Investigation of the alternatively spliced insert region of the D2L dopamine receptor by epitope substitution. Neurosci Lett. 2006 Jan 30;393(2-3):155-9. Epub 2005 Oct 12. PubMed PMID: 16226376.
  • Everett PB, Senogles SE. D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway. Neurosci Lett. 2004 Nov 16;371(1):34-9. PubMed PMID: 15500962.

View more references (pubmed link)